We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain—The Fostasur Study.
- Authors
Jiménez‐Bárcenas, Reyes; García‐Donas‐Gabaldón, Gloria; Campos‐Álvarez, Rosa María; Fernández‐Sánchez de Mora, María Carmen; Luis‐Navarro, Josefa; Domínguez‐Rodríguez, Juan Francisco; Nieto‐Hernández, María del Mar; Sánchez‐Bazán, Irene; Yera‐Cobo, Maria; Cardesa‐Cabrera, Rocio; Jiménez‐Gonzalo, Francisco José; Ruiz‐Cobo, María Antonia; Caparrós‐Miranda, Isabel; Entrena‐Ureña, Laura; Fernández Jiménez, Dolores; Díaz‐Canales, Dana; Moreno‐Carrasco, Gloria; Calderón‐Cabrera, Cristina; Núñez‐Vázquez, Ramiro José; Pedrote‐Amador, Begoña
- Abstract
Summary: Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second‐line treatment for ITP. Real‐world data on fostamatinib are lacking. This observational, retrospective, multicentre study, conducted in the Andalusia region of Spain, evaluated 44 adult primary ITP patients (47.7% female; median age 58 years; newly diagnosed ITP 6.8%; persistent 13.6%; chronic 79.5%; median four prior treatments) after ≥ 4 weeks of fostamatinib therapy. The median PLT at the initiation of fostamatinib was 15 × 109/L. Common reasons for starting fostamatinib were refractoriness or intolerance to prior therapy, oral medication preference, history of thrombosis and cardiovascular risk. Dosing was individualized based on efficacy and tolerance. After 2 weeks, global response rate was 56.8% (response and complete response). Response rates were 70.5%, 62.5% and 64% at 4 weeks, 12 weeks and at the end of the study respectively. Adverse events were mild, and no patients discontinued as a result. This real‐world study demonstrated a response rate similar to fostamatinib as seen in the pivotal clinical trials while including newly diagnosed patients and allowing for individualized dosing.
- Subjects
ANDALUSIA (Spain); SPAIN; IDIOPATHIC thrombocytopenic purpura; PROTEIN-tyrosine kinase inhibitors; PLATELET count; ORAL medication; CARDIOVASCULAR diseases risk factors
- Publication
British Journal of Haematology, 2024, Vol 204, Issue 5, p1977
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.19443